Thanks for posting that, gg cox.
"Regulators in Europe are expected to make a decision as soon as next week about whether to take any action on the drugs. The F.D.A.'s expert panel will review whether Celebrex and Bextra are safe, Dr. Sandra Kweder, acting director of the administration's office of new drugs, said in an interview yesterday."
Wow, next week could be a significant week for the stock price of DMX if Europe makes any kind of decision to broaden the CoxII ban. I'll be watching the newswires vigilantly.
"While no study of either drug analyzed by the agency so far has been cause for concern, Dr. Kweder said, the agency is not sure it has all the information it needs. The agency is aware of the two studies involving the intravenous form of Bextra, but "it's unclear what the relationship is with the oral form," she said.
Other recent studies suggesting that all COX-2 inhibitors may have safety problems are still being analyzed by the agency, she said. Uncertainty over the safety of drugs is not uncommon, Dr. Kweder said, and that is "something we have to take into account with regard to every decision we make about marketing a new drug and every decision we make about withdrawal of a drug."
But some doctors say because the benefits of COX-2 drugs are so unclear, the advantages of taking one of these painkillers may not outweigh these risks.
"You have to treat people who are high risk conservatively," Dr. Campen said."
Certainly the story is far from over in the US as well. Sounds like a few skeletons may still be in the closet there.
The world continues to look better for Pennsaid.
joe |
